FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:2142-2143 May 14, 2009 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

To the Editor: In their letter to the editor about eculizumab for congenital atypical hemolytic–uremic syndrome, Gruppo and Rother (Jan. 29 issue)¹ report that they used eculizumab in an 18-month-old boy at an initial dose of 300 mg and a maintenance dose of 600 mg — half and two thirds of the adult doses (600 mg and 900 mg), respectively.² These doses may be relatively high, because this patient weighed only 12 kg, and the body-surface area is approximately 0.5 m², which may be less than one third of the adult area. The appropriate dose and the pharmacokinetics of . . . [Full Text of this Article]

Related Letters:

Eculizumab for Congenital Atypical Hemolytic–Uremic Syndrome
Gruppo R. A., Rother R. P.
Extract | Full Text | PDF  
N Engl J Med 2009; 360:544-546, Jan 29, 2009. Correspondence

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.